DDX59-AS1: A Novel Prognostic Biomarker and Immunotherapy Predictor in Lung Adenocarcinoma.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current medicinal chemistry Pub Date : 2025-02-18 DOI:10.2174/0109298673359149250212073143

Yanli Wang, Wei Li, Su Wei, Lixi Zhang, Dongbing Li, Xu Qi

{"title":"DDX59-AS1: A Novel Prognostic Biomarker and Immunotherapy Predictor in Lung Adenocarcinoma.","authors":"Yanli Wang, Wei Li, Su Wei, Lixi Zhang, Dongbing Li, Xu Qi","doi":"10.2174/0109298673359149250212073143","DOIUrl":null,"url":null,"abstract":"Background: The precise function of DDX59 Antisense RNA 1 (DDX59- AS1) in lung adenocarcinoma (LUAD) has yet to be fully elucidated.Objective: This study uses bioinformatics analysis and experimental validation to investigate the association between DDX59-AS1 and LUAD.Methods: This study uses statistical analysis and database interrogation to investigate the potential association between DDX59-AS1 expression and various clinical characteristics, prognostic factors, regulatory networks, and immune infiltration in LUAD. The quantification of DDX59-AS1 expression in LUAD cell lines is conducted through the use of quantitative real-time polymerase chain reaction (qRT-PCR).Results: DDX59-AS1 showed significantly elevated levels of expression in patients with LUAD. High levels of DDX59-AS1 expression were found to be significantly associated with poorer overall survival (OS) in patients with LUAD (p = 0.024). Furthermore, an independent correlation was observed between high DDX59-AS1 expression (p = 0.037) and OS in LUAD patients. DDX59-AS1 was found to be involved in various pathways, including glutathione metabolism, proteasome function, and the cytosolic DNA sensing pathway, among others. A significant correlation was observed between the expression levels of DDX59-AS1 and immune cell infiltration in the context of LUAD. Notably, elevated expression of DDX59-AS1 was observed in LUAD cell lines compared to the non-cancerous Beas-2B cell line.Conclusion: A significant correlation was observed between elevated DDX59-AS1 expression in patients with LUAD and adverse prognosis, alongside increased immune infiltration. These results indicate that DDX59-AS1 may function as a prognostic marker for LUAD and a potential predictor of immunotherapy response.","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673359149250212073143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The precise function of DDX59 Antisense RNA 1 (DDX59- AS1) in lung adenocarcinoma (LUAD) has yet to be fully elucidated.

Objective: This study uses bioinformatics analysis and experimental validation to investigate the association between DDX59-AS1 and LUAD.

Methods: This study uses statistical analysis and database interrogation to investigate the potential association between DDX59-AS1 expression and various clinical characteristics, prognostic factors, regulatory networks, and immune infiltration in LUAD. The quantification of DDX59-AS1 expression in LUAD cell lines is conducted through the use of quantitative real-time polymerase chain reaction (qRT-PCR).

Results: DDX59-AS1 showed significantly elevated levels of expression in patients with LUAD. High levels of DDX59-AS1 expression were found to be significantly associated with poorer overall survival (OS) in patients with LUAD (p = 0.024). Furthermore, an independent correlation was observed between high DDX59-AS1 expression (p = 0.037) and OS in LUAD patients. DDX59-AS1 was found to be involved in various pathways, including glutathione metabolism, proteasome function, and the cytosolic DNA sensing pathway, among others. A significant correlation was observed between the expression levels of DDX59-AS1 and immune cell infiltration in the context of LUAD. Notably, elevated expression of DDX59-AS1 was observed in LUAD cell lines compared to the non-cancerous Beas-2B cell line.

Conclusion: A significant correlation was observed between elevated DDX59-AS1 expression in patients with LUAD and adverse prognosis, alongside increased immune infiltration. These results indicate that DDX59-AS1 may function as a prognostic marker for LUAD and a potential predictor of immunotherapy response.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

DDX59-AS1：肺腺癌新的预后生物标志物和免疫治疗预测因子

背景：DDX59反义RNA 1 （DDX59- AS1）在肺腺癌（LUAD）中的确切功能尚未完全阐明。目的：通过生物信息学分析和实验验证，探讨DDX59-AS1与LUAD的相关性。方法：采用统计学分析和数据库查询的方法，探讨DDX59-AS1表达与LUAD的各种临床特征、预后因素、调节网络和免疫浸润之间的潜在关联。DDX59-AS1在LUAD细胞系中的表达通过定量实时聚合酶链式反应（qRT-PCR）进行定量。结果：DDX59-AS1在LUAD患者中表达水平明显升高。发现高水平的DDX59-AS1表达与LUAD患者较差的总生存期（OS）显著相关（p = 0.024）。此外，在LUAD患者中，DDX59-AS1高表达与OS之间存在独立相关性（p = 0.037）。DDX59-AS1被发现参与多种途径，包括谷胱甘肽代谢、蛋白酶体功能和细胞质DNA传感途径等。在LUAD背景下，DDX59-AS1的表达水平与免疫细胞浸润之间存在显著相关性。值得注意的是，与非癌性Beas-2B细胞系相比，在LUAD细胞系中观察到DDX59-AS1的表达升高。结论：LUAD患者DDX59-AS1表达升高与不良预后显著相关，且免疫浸润增加。这些结果表明，DDX59-AS1可能作为LUAD的预后标记物和免疫治疗反应的潜在预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.